• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Legend Biotech Corporation

    3/25/25 12:15:16 PM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LEGN alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001796536
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Legend Biotech Corp
    SEC File Number
    001-39307
    Address of Issuer
    2101 COTTONTAIL LANE
    SOMERSET
    NEW JERSEY
    08873
    Phone
    732-850-5598
    Name of Person for Whose Account the Securities are To Be Sold
    Sanders Corazon (Corsee) D.
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    American Depositary Shares
    Fidelity Brokerage Services LLC
    900 Salem Street
    Smithfield � RI � 02917
    30711153.3136729831503/25/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    American Depositary Shares03/20/2025Restricted Stock VestingIssuerCheckbox not checked30703/20/2025Compensation

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Date of Notice
    03/25/2025
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    11/14/2024

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/Wade Moss, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Corazon D Sanders

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $LEGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LEGN

    DatePrice TargetRatingAnalyst
    10/8/2024$86.00Buy
    Redburn Atlantic
    6/17/2024$88.00Buy
    Truist
    5/24/2024$86.00 → $73.00Buy
    H.C. Wainwright
    5/23/2024$60.00Buy
    Deutsche Bank
    4/17/2024$65.00Sector Perform → Sector Outperform
    Scotiabank
    4/3/2024$82.00Overweight
    Cantor Fitzgerald
    3/13/2024$86.00Outperform
    Raymond James
    12/19/2023Sector Perform
    Scotiabank
    More analyst ratings

    $LEGN
    Leadership Updates

    Live Leadership Updates

    See more
    • Legend Biotech Appoints Alan Bash as President of CARVYKTI®

      SOMERSET, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, today announced the appointment of Alan Bash as the Company's President of CARVYKTI®. In this newly created role, Mr. Bash will be responsible for managing the continued growth of CARVYKTI®, overseeing Legend Biotech's commercial, technical operations, and quality functions of the franchise. "This expansion in our leadership structure is on the heels of CARVYKTI's recent successes, including recent approvals from the U.S. Food and Drug Administration and European Commission for label expansion," said Ying Huang, Ph.D., Chief Executive Officer of Leg

      11/4/24 7:30:00 AM ET
      $LEGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia

      SOMERSET, N.J., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), announced it is establishing a new, state-of-the-art research and development (R&D) facility in Philadelphia, Pennsylvania, to advance its portfolio of next-generation cell therapies. "This new facility underscores Legend's commitment to R&D, as we make key investments that will advance our pipeline and strengthen our leadership position in cell therapy innovation," said Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech. "We are excited to join the Philadelphia biotech community, a growing innovation hub and a prime location to attract top talent and strengthen our partn

      10/3/24 7:30:00 AM ET
      $LEGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Legend Biotech Appoints Peter Salovey, Ph.D., to its Board of Directors

      SOMERSET, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, today announced the appointment of Peter Salovey, Ph.D., President Emeritus of Yale University, to its Board of Directors. Dr. Salovey will serve as an independent director, effective August 9. "We are pleased to welcome Dr. Salovey to the Legend Board," said Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech. "Dr. Salovey's deep experience and wealth of knowledge in medical research and public health will be invaluable to Legend and offer a new and diverse perspective. We look forward to his insights and contributions to the strategic dec

      8/8/24 4:05:00 PM ET
      $LEGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LEGN
    Financials

    Live finance-specific insights

    See more

    $LEGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $LEGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $LEGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $LEGN
    SEC Filings

    See more
    • Legend Biotech to Host Investor Conference Call on First Quarter 2025 Results

      SOMERSET, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Tuesday, May 13, 2025, to review first-quarter 2025 results. During the webcast and conference call, senior leaders will provide an overview of Legend Biotech's performance for the quarter. Investors and other interested parties may join the live audio webcast of the call via this weblink. A replay of the webcast and earnings news release will be available through the Investor Relations section of Legend Biotech's website under the Events and Presentations section approximately two hours

      4/29/25 8:00:00 AM ET
      $LEGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Legend Biotech Reports Fourth Quarter and Full Year 2024 Results and Recent Highlights

      CARVYKTI® net trade sales of approximately $334 million and $963 million for the fourth quarter and full year 2024, respectivelyOver 5,000 patients treated to dateInitiated commercial production of CARVYKTI® at a Novartis production facilitySpain's national health system approved reimbursement for CARVYKTI® in second-line plus settings for multiple myeloma patientsCash and cash equivalents, and time deposits of $1.1 billion, as of December 31, 2024, which Legend Biotech believes will provide financial runway into the second quarter of fiscal year 2026 SOMERSET, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell thera

      3/11/25 7:00:00 AM ET
      $LEGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2024 Results

      SOMERSET, N.J., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Tuesday, March 11, 2025, to review fourth-quarter and full-year 2024 results. During the webcast and conference call, senior leaders will provide an overview of Legend Biotech's quarter and fiscal year performance. Investors and other interested parties may join the live audio webcast of the call via this weblink. A replay version of the webcast and earnings news release will be available through the Investor Relations section of Legend Biotech's website under the Events and Presentation s

      2/25/25 8:00:00 AM ET
      $LEGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Redburn Atlantic initiated coverage on Legend Biotech with a new price target

      Redburn Atlantic initiated coverage of Legend Biotech with a rating of Buy and set a new price target of $86.00

      10/8/24 7:29:11 AM ET
      $LEGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Truist initiated coverage on Legend Biotech with a new price target

      Truist initiated coverage of Legend Biotech with a rating of Buy and set a new price target of $88.00

      6/17/24 7:33:12 AM ET
      $LEGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright reiterated coverage on Legend Biotech with a new price target

      H.C. Wainwright reiterated coverage of Legend Biotech with a rating of Buy and set a new price target of $73.00 from $86.00 previously

      5/24/24 7:45:26 AM ET
      $LEGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Legend Biotech to Host Investor Conference Call on First Quarter 2025 Results

      SOMERSET, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Tuesday, May 13, 2025, to review first-quarter 2025 results. During the webcast and conference call, senior leaders will provide an overview of Legend Biotech's performance for the quarter. Investors and other interested parties may join the live audio webcast of the call via this weblink. A replay of the webcast and earnings news release will be available through the Investor Relations section of Legend Biotech's website under the Events and Presentations section approximately two hours

      4/29/25 8:00:00 AM ET
      $LEGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Legend Biotech Reports Fourth Quarter and Full Year 2024 Results and Recent Highlights

      CARVYKTI® net trade sales of approximately $334 million and $963 million for the fourth quarter and full year 2024, respectivelyOver 5,000 patients treated to dateInitiated commercial production of CARVYKTI® at a Novartis production facilitySpain's national health system approved reimbursement for CARVYKTI® in second-line plus settings for multiple myeloma patientsCash and cash equivalents, and time deposits of $1.1 billion, as of December 31, 2024, which Legend Biotech believes will provide financial runway into the second quarter of fiscal year 2026 SOMERSET, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell thera

      3/11/25 7:00:00 AM ET
      $LEGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2024 Results

      SOMERSET, N.J., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Tuesday, March 11, 2025, to review fourth-quarter and full-year 2024 results. During the webcast and conference call, senior leaders will provide an overview of Legend Biotech's quarter and fiscal year performance. Investors and other interested parties may join the live audio webcast of the call via this weblink. A replay version of the webcast and earnings news release will be available through the Investor Relations section of Legend Biotech's website under the Events and Presentation s

      2/25/25 8:00:00 AM ET
      $LEGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Legend Biotech Corporation

      SC 13G/A - Legend Biotech Corp (0001801198) (Subject)

      11/14/24 1:22:39 PM ET
      $LEGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Legend Biotech Corporation

      SC 13G/A - Legend Biotech Corp (0001801198) (Subject)

      11/12/24 10:32:10 AM ET
      $LEGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Legend Biotech Corporation (Amendment)

      SC 13G/A - Legend Biotech Corp (0001801198) (Subject)

      4/5/24 12:18:27 PM ET
      $LEGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Legend Biotech Corporation

      6-K - Legend Biotech Corp (0001801198) (Filer)

      4/15/25 7:30:15 AM ET
      $LEGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Legend Biotech Corporation

      144 - Legend Biotech Corp (0001801198) (Subject)

      3/25/25 12:15:16 PM ET
      $LEGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 20-F filed by Legend Biotech Corporation

      20-F - Legend Biotech Corp (0001801198) (Filer)

      3/11/25 4:02:47 PM ET
      $LEGN
      Biotechnology: Pharmaceutical Preparations
      Health Care